文献速递其他结缔组织病

新型自身抗原真核起始因子3与多发性肌炎相关

Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

研究在678例多发性肌炎(PM)患者中检测针对新型自身抗原真核起始因子3(eIF3)的自身抗体,发现3例(0.44%)阳性,该抗体未见于疾病对照或健康对照血清。3例抗eIF3阳性患者均无恶性肿瘤或间质性肺病史,且对治疗反应良好,提示该抗体可能与良好预后相关。

要点

  • 在678例PM患者中,抗eIF3抗体阳性率为0.44%(3例)。
  • 抗eIF3抗体未在疾病对照或健康对照血清中检出。
  • 3例阳性患者无恶性肿瘤或间质性肺病史,治疗反应良好。

核心结论

  • 在多发性肌炎患者中发现针对真核起始因子3(eIF3)的新型自身抗体,阳性率为0.44%。
  • 抗eIF3抗体可能与良好预后和治疗反应良好相关,但需进一步确认。

研究设计与样本

  • 对678例PM患者的血清或血浆采用放射性标记蛋白免疫沉淀(IPP)分析自身抗原特异性。
  • 对免疫沉淀相同新型自身抗原的样本进行间接免疫荧光和预清除细胞提取物IPP分析。
  • 通过IPP联合MALDI-TOF质谱鉴定自身抗原,并用商业抗体和IPP-免疫印迹确认。
  • 对668例DM、80例DM重叠、191例PM重叠、150例系统性硬化、200例SLE、40例干燥综合征、50例RA患者及150例健康对照的样本进行IPP血清分型。

主要发现

  • IPP在3例PM患者(0.44%)中显示新型模式,未见于疾病特异性或健康对照血清。
  • 间接免疫荧光显示所有阳性患者呈细细胞质斑点型。
  • 质谱分析鉴定靶自身抗原为eIF3,一种参与翻译起始的细胞质复合物。
  • IPP-免疫印迹确认了上述发现。
  • 3例抗eIF3阳性患者无恶性肿瘤或间质性肺病史,对治疗反应良好。

关键数值与推荐

  • 抗eIF3抗体在PM患者中的阳性率为0.44%(3/678)。
  • 抗eIF3抗体在疾病对照(DM、DM重叠、PM重叠、系统性硬化、SLE、干燥综合征、RA)和健康对照中未检出。

临床怎么用

  • 抗eIF3抗体可作为PM的一种新型血清学标志物,阳性率虽低但具有特异性。
  • 抗eIF3阳性可能提示无恶性肿瘤或间质性肺病,且对治疗反应良好,但需进一步验证。

局限性

  • 抗eIF3阳性患者仅3例,样本量小,结论需进一步确认。
  • 研究未报告抗eIF3抗体与临床特征关联的统计学分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe the prevalence and clinical associations of autoantibodies to a novel autoantigen, eukaryotic initiation factor 3 (eIF3), detected in idiopathic inflammatory myositis. METHODS: Sera or plasma from 678 PM patients were analysed for autoantigen specificity by radio-labelled protein immunoprecipitation (IPP). Samples immunoprecipitating the same novel autoantigens were further analysed by indirect immunofluorescence and IPP using pre-depleted cell extracts. The autoantigen was identified through a combination of IPP and MALDI-TOF mass spectrometry, and confirmed using commercial antibodies and IPP-western blots. Additional samples from patients with DM (668), DM-overlap (80), PM-overlap (191), systemic sclerosis (150), systemic lupus erythematosus (200), Sjogren's syndrome (40), rheumatoid arthritis (50) and healthy controls (150) were serotyped by IPP as disease or healthy controls. RESULTS: IPP revealed a novel pattern in three PM patients (0.44%) that was not found in disease-specific or healthy control sera. Indirect immunofluorescence demonstrated a fine cytoplasmic speckled pattern for all positive patients. Mass spectrometry analysis of the protein complex identified the target autoantigen as eIF3, a cytoplasmic complex with a role in the initiation of translation. Findings were confirmed by IPP-Western blotting. The three anti-eIF3-positive patients had no history of malignancy or interstitial lung disease, and had a favourable response to treatment. CONCLUSION: We report a novel autoantibody in 0.44% of PM patients directed against a cytoplasmic complex of proteins identified as eIF3. Although our findings need further confirmation, anti-eIF3 appears to correlate with a good prognosis and a favourable response to treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Betteridge Z, Chinoy H, Vencovsky J, et al. Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. Rheumatology (Oxford). 2020. PMID: 31728542. doi:10.1093/rheumatology/kez406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。